United States of America - The manufacturer of filgrastim (Neupogen®) 300 µg vials in ten-pack boxes has reported the existence of a counterfeit product. Neupogen is primarily used to prevent infection, as manifested by febrile neutropenia in cancer patients receiving myelotoxic chemotherapy.

The counterfeit vials examined contain a clear liquid but no active ingredient. This counterfeit product could pose a serious health risk to patients, and pharmacists and other health care providers should examine the product before use. Information, including pictures illustrating differences, are available on the manufacturer’s Website. The counterfeit product has so far only been found in distribution in the USA.

Reference: Information from Amgen dated 10 May 2001 at http://www.amgen.com/news